JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

96.7 0.54

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

95.92

Max

98.09

Galvenie mērījumi
By Trading Economics
Ienākumi	-125M 299M
Pārdošana	141M 1.5B
P/E Sektora vidējais	15.12 60.328
Peļņas marža	19.861
Darbinieki	2,844
EBITDA	-92M 415M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+11.65% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2.1B 19B
Iepriekšējā atvēršanas cena	96.16
Iepriekšējā slēgšanas cena	96.7

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. apr. 00:00 UTC

Galvenie ziņu notikumi

Australian Flash PMI Bounce in April Conceals Deeper Worries

2026. g. 22. apr. 23:33 UTC

Peļņas

SK Hynix Posts Record Quarterly Results Amid AI Boom

2026. g. 22. apr. 22:40 UTC

Peļņas

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

2026. g. 22. apr. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

2026. g. 22. apr. 21:11 UTC

Peļņas

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

2026. g. 22. apr. 21:01 UTC

Peļņas

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

2026. g. 22. apr. 23:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 22. apr. 23:46 UTC

Tirgus saruna

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

2026. g. 22. apr. 23:34 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

2026. g. 22. apr. 23:16 UTC

Peļņas

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

2026. g. 22. apr. 23:15 UTC

Peļņas

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

2026. g. 22. apr. 22:54 UTC

Peļņas

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 22. apr. 22:54 UTC

Peļņas

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

2026. g. 22. apr. 22:52 UTC

Peļņas

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

2026. g. 22. apr. 22:51 UTC

Peļņas

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

2026. g. 22. apr. 22:31 UTC

Peļņas

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

2026. g. 22. apr. 22:31 UTC

Peļņas

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

2026. g. 22. apr. 22:30 UTC

Peļņas

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

2026. g. 22. apr. 22:30 UTC

Peļņas

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

2026. g. 22. apr. 22:29 UTC

Peļņas

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

2026. g. 22. apr. 22:28 UTC

Peļņas

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

2026. g. 22. apr. 22:28 UTC

Peļņas

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

2026. g. 22. apr. 22:27 UTC

Peļņas

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

2026. g. 22. apr. 22:06 UTC

Tirgus saruna

Peļņas

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

2026. g. 22. apr. 21:55 UTC

Iegādes, apvienošanās, pārņemšana

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

2026. g. 22. apr. 21:47 UTC

Peļņas

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 22. apr. 21:37 UTC

Peļņas

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

2026. g. 22. apr. 21:34 UTC

Peļņas

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

2026. g. 22. apr. 21:29 UTC

Peļņas

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 22. apr. 21:20 UTC

Tirgus saruna

Peļņas

Tesla Expands Manufacturing to Chips -- Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

11.65% augšup

Prognoze 12 mēnešiem

Vidējais 107.43 USD 11.65%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation